Cipla Limited — Sulfamethoxazole Exporter Profile
Indian Pharmaceutical Exporter · #11 for Sulfamethoxazole · $404.2K export value · DGFT Verified
Cipla Limited is the #11 Indian exporter of Sulfamethoxazole with $404.2K in export value and 38 verified shipments. Cipla Limited holds a 2.0% market share in Sulfamethoxazole exports across 6 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
Cipla Limited — Sulfamethoxazole Export Profile: Buyers & Destinations
Where Does Cipla Limited Export Sulfamethoxazole?
| Country | Value | Shipments | Share |
|---|---|---|---|
| GUINEA | $217.1K | 9 | 53.7% |
| SOUTH SUDAN | $98.1K | 3 | 24.3% |
| EQUATORIAL GUINEA | $31.8K | 5 | 7.9% |
| FRANCE | $24.3K | 16 | 6.0% |
| BELGIUM | $23.2K | 4 | 5.7% |
| SUDAN | $9.8K | 1 | 2.4% |
Cipla Limited exports Sulfamethoxazole to 6 countries. The largest destination is GUINEA accounting for 53.7% of Cipla Limited's Sulfamethoxazole shipments, followed by SOUTH SUDAN (24.3%) and EQUATORIAL GUINEA (7.9%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Sulfamethoxazole from Cipla Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| MINISTERE DE LA SANTE | GUINEA | $119.2K | 4 |
| UNDP SOUTH SUDAN | SOUTH SUDAN | $98.1K | 3 |
| MINISTERE DE LA SANTE PROGRAMME | GUINEA | $97.8K | 5 |
| MSF LOGISTIQUE - BORDEAUX | FRANCE | $19.5K | 13 |
| MSF SUPPLY | BELGIUM | $17.2K | 3 |
| MINISTERIO DE SANIDAD AND BIENESTAR | EQUATORIAL GUINEA | $13.9K | 1 |
| DIRECTOR GENERAL | SUDAN | $9.8K | 1 |
| UNDP GUINEA ECUATORIAL AUTOVA DEL | EQUATORIAL GUINEA | $9.1K | 1 |
| UNDP EQUATORIAL GUINEA EDIFICIO DE | EQUATORIAL GUINEA | $8.8K | 3 |
| MSF SUPPLY CHAUSSE DE | BELGIUM | $6.0K | 1 |
Cipla Limited supplies Sulfamethoxazole to 11 buyers globally. The largest buyer is MINISTERE DE LA SANTE (GUINEA), followed by UNDP SOUTH SUDAN (SOUTH SUDAN) and MINISTERE DE LA SANTE PROGRAMME (GUINEA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Sulfamethoxazole Export Value and How Much Does Cipla Limited Contribute?
India exported $12.2M worth of Sulfamethoxazole through 877 shipments from 145 suppliers to 92 countries, serving 266 buyers globally. Cipla Limited contributes $404.2K to this total, accounting for 2.0% of India's Sulfamethoxazole exports. Cipla Limited ships Sulfamethoxazole to 6 countries through 11 buyers.
What Is the Average Shipment Value for Cipla Limited's Sulfamethoxazole Exports?
Cipla Limited's average Sulfamethoxazole shipment value is $10.6K per consignment, based on 38 shipments totaling $404.2K. The largest destination is GUINEA (53.7% of Cipla Limited's Sulfamethoxazole exports).
How Does Cipla Limited Compare to Other Indian Sulfamethoxazole Exporters?
Cipla Limited ranks #11 among 145 Indian Sulfamethoxazole exporters with a 2.0% market share. The top 3 exporters are MICRO LABS LIMITED ($5.5M), FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED ($1.0M), AUROBINDO PHARMA LIMITED ($950.0K). Cipla Limited processed 38 shipments to 6 destination countries.
What Sulfamethoxazole Formulations Does Cipla Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| Q-TIB TABLETS SULFAMETHOXAZOLE TRIMETH | $92.9K | 5 |
| Q-TIB TAB.(SULFAMETHOXAZOLE,TRIMETHOPRIM | $66.4K | 2 |
| Q-TIB TABLETSSULFAMETHOXAZOLE,TRIMETHOP | $57.8K | 3 |
| Q-TIB TABLETSULFAMETHOXAZOLETRIMETHOPR | $40.0K | 2 |
| Q-TIB TABLETS SULFAMETHOXAZOLETRIMETHO | $34.9K | 2 |
| Q-TIB TABLETS(SULFAMETHOXAZOLE,TRIMETHOP | $33.5K | 9 |
| Q-TIB TAB (SULFAMETHOXAZOLE,TRIMETHOPRIM | $31.7K | 1 |
| Q-TIB TABLETS(SULFAMETHOXAZOLE, TRIMETHO | $12.9K | 1 |
| Q-TIB TABLETS (SULFAMETHOXAZOLE,TRIMETHO | $9.6K | 4 |
| Q-TIB TABLETSSULFAMETHOXAZOLETRIMETHOPRIMISONIAZID PYRIDOXINE HYDROCHLORIDE TAB 800/160/300/25MG3609PACKx1X 30'S=1 | $8.6K | 1 |
Cipla Limited exports 15 distinct Sulfamethoxazole formulations including tablets, capsules, syrups, and combination drugs. The top formulation is Q-TIB TABLETS SULFAMETHOXAZOLE TRIMETH with 5 shipments worth $92.9K.
How Does Cipla Limited Compare to Nearest Sulfamethoxazole Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | MEDREICH LIMITED | $454.4K | 20 | 1 | $22.7K |
| 10 | MEDICAMEN BIOTECH LIMITED | $442.8K | 18 | 2 | $24.6K |
| 11 | CIPLA LIMITED ★ | $404.2K | 38 | 6 | $10.6K |
| 12 | SYNCOM FORMULATIONS (INDIA) LIMITED | $395.8K | 43 | 5 | $9.2K |
| 6 | MICRO LABS LTD | $300.0K | 6 | 3 | $50.0K |
Cipla Limited ranks #11 among 145 Indian Sulfamethoxazole exporters. Average shipment value of $10.6K compared to the market average of $84.0K. The closest competitors by value are MEDREICH LIMITED and MEDICAMEN BIOTECH LIMITED.
Which Indian Ports Ship Sulfamethoxazole Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 85 | 9.7% |
| JNPT/ NHAVA SHEVA SEA | 83 | 9.5% |
| SAHAR AIR | 72 | 8.2% |
| JNPT | 65 | 7.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 62 | 7.1% |
| PITHAMPUR ICD | 42 | 4.8% |
| APIIC PHARMA SEZ | 24 | 2.7% |
| NHAVA SHEVA | 24 | 2.7% |
Geopolitical & Trade Policy Impact on Cipla Limited's Sulfamethoxazole Exports
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Cipla Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
About Cipla Limited
Cipla Limited exports 98 products worth $1.1B. Beyond Sulfamethoxazole, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Sulfamethoxazole — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Sulfamethoxazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Cipla Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 38 individual customs records matching Cipla Limited exporting Sulfamethoxazole, covering 15 formulations to 6 countries via 11 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 92+ countries, 266+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Sulfamethoxazole Export Data from Cipla Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Sulfamethoxazole exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Sulfamethoxazole Stats
Company Overview
Top Products by Cipla Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Sulfamethoxazole. For current shipment-level data, contact TransData Nexus.